The effectiveness of CAR T cell therapy against a variety of cancers, including solid tumors, could be boosted greatly by using CRISPR-Cas9 technology to knock out the gene for CD5, a protein found on ...
A phase 2 study to confirm safety and efficacy of MB-105, an autologous CD5-directed CAR T-cell therapy, in relapsed/refractory T-cell lymphoma (R/R TCL). This is an ASCO Meeting Abstract from the ...
The effectiveness of CAR T cell therapy against a variety of cancers, including solid tumors, could be boosted greatly by using CRISPR-Cas9 technology to knock out the gene for CD5, a protein found on ...
PHILADELPHIA-- Knocking out a protein known to stifle T cell activation on CAR T cells using the CRISPR/Cas9 technology enhanced the engineered T cells' ability to eliminate blood cancers, according ...
Scientists at the Washington University School of Medicine in St. Louis report that the difference between people who do and do not respond to immunotherapy may have to do with CD5 + dendritic cells ...
Cancer immunotherapy involves using activated T cells to destroy tumors, but it doesn't work for all patients. Researchers have discovered that a kind of dendritic cell is crucial for determining the ...
PHILADELPHIA – The effectiveness of CAR T cell therapy against a variety of cancers, including solid tumors, could be boosted greatly by using CRISPR-Cas9 technology to knock out the gene for CD5, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results